Qiagen's Q3 Revenues Rise 50 Percent, But Acquisition Costs Hit Bottom Line

genomeweb
360dx

Qiagen's Q3 Revenues Rise 50 Percent, But Acquisition Costs Hit Bottom Line

Nov 06, 2007

NEW YORK (GenomeWeb News) – Qiagen yesterday said that its third-quarter revenues rose 50 percent year over year, but acquisition-related charges and a 77 percent increase in R&D costs swung the company from a profit to a loss.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

Hologic M. Genitalium Assay Gets FDA De Novo Clearance
Biocartis Raises €55.5M in Equity Placement
Long-Read Genome Assemblies Have Many Errors in Protein-Coding Regions, Study Finds
Microbial Genomics Firm uBiome Lays Off 55 Employees
SpeeDx Signs Distribution Deals in Finland, Italy
Infectious Disease Firm Day Zero Diagnostics Raises $8.6M in Series A Round

The Scan

No Flu for These Birds

Reuters reports that UK researchers are using gene-editing tools to develop flu-resistant chickens.

To Track Cholera

Nature calls for genomics to become part of the World Health Organization's cholera surveillance approach.

Better Odds?

Vox explores a proposal to institute a lottery system to award grant funds.

This Week in Genome Biology

In Genome Biology this week: gut microbiome study of individuals from Tanzania and Botswana, sixth version of the Network of Cancer Genes database, and more.

Main menu